Literature DB >> 20305599

Othello syndrome in patients with Parkinson's disease.

Dejan Georgiev1, Aljosa Danieli, Lidija Ocepek, Dominika Novak, Nina Zupancic-Kriznar, Maja Trost, Zvezdan Pirtosek.   

Abstract

BACKGROUND: Othello syndrome (OS) is an organic delusional disorder with prevailing jealousy symptoms presumably appearing as side effect of antiparkinsonian therapy. The clinical spectrum of psychiatric symptoms in Parkinson's disease (PD) is very wide, including symptoms of depression and anxiety, hallucinations, delusions, with prevalent paranoid symptoms, agitation, delirium and sleep disorders. At our knowledge, just a few cases of patients with PD and OS were reported till now.
METHODS: three neurologists working in a tertiary referral centre were asked to report cases of pathological jealousy as defined by the DSM IV criteria (Kaplan et al. 1994). The following data were collected retrospectively: sex, age at PD onset, age at OS onset, duration of PD, duration of PD treatment, duration of treatment with dopamine agonists (DAs), treatment of OS, past history of alcoholism, premorbid personality disorder, family history of psychiatric disorders and data about general cognitive condition.
RESULTS: Five PD patients (three males) with OS were investigated. The mean age of the patients at the PD onset was 46.80+/-8.87 (SD), the mean age at the OS onset was 56.40+/-8.76 (SD). Before the onset of OS, all of them were taking dopamine agonists. The first patient was treated with pramipexole, apomorphine infusion and levodopa/carbidopa, the second with apomorphine infusion plus levodopa/carbidopa/entacapone, the third with pramipexole, the fourth and fifth with ropinirole. Decrease of dopamine agonist led to clinical improvement in three patients (complete reduction of the symptoms in two, reduction of symptoms in one patients). In two patients, the symptoms remained the same. In three patients atypical neuroleptics had to be added: clozapine in two and quetiapine in one patient.
CONCLUSIONS: We believe that OS is a more common psychiatric side effect in PD patients on treatment with dopamine agonists than usually believed, particulary in those with early disease onset. It is a very disturbing symptom for patients and their partners, often underestimated by them, and should therefore be actively searched for.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20305599

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  14 in total

Review 1.  Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.

Authors:  Niyatee Samudra; Neepa Patel; Kyle B Womack; Pravin Khemani; Shilpa Chitnis
Journal:  Drugs Aging       Date:  2016-12       Impact factor: 3.923

2.  Dopamine agonists and Othello's syndrome.

Authors:  Jonathan Graff-Radford; J Eric Ahlskog; James H Bower; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2010-09-09       Impact factor: 4.891

3.  Available and future treatments for atypical parkinsonism. A systematic review.

Authors:  Davide Vito Moretti
Journal:  CNS Neurosci Ther       Date:  2018-10-07       Impact factor: 5.243

4.  Resolution of Othello Syndrome After Subthalamic Nucleus Deep Brain Stimulation in 3 Patients with Parkinson's Disease.

Authors:  Robert J Adam; Robert McLeod; Ainhi D Ha; James G Colebatch; Graham Menzies; Gregory de Moore; Neil Mahant; Victor S C Fung
Journal:  Mov Disord Clin Pract       Date:  2014-09-16

5.  Phenomenology and predisposing factors of morbid jealousy in a psychiatric outdoor: a cross-sectional, descriptive study.

Authors:  Satyajeet Kumar Singh; Samrat Singh Bhandari; Pramod Kumar Singh
Journal:  Open J Psychiatry Allied Sci       Date:  2017-04-26

Review 6.  Intention, false beliefs, and delusional jealousy: insights into the right hemisphere from neurological patients and neuroimaging studies.

Authors:  Stephanie Ortigue; Francesco Bianchi-Demicheli
Journal:  Med Sci Monit       Date:  2011-01

7.  Ellagic acid improves hyperalgesia and cognitive deficiency in 6-hydroxidopamine induced rat model of Parkinson's disease.

Authors:  Mojtaba Dolatshahi; Yaghoob Farbood; Alireza Sarkaki; Seyed Mohammad Taqhi Mansouri; Ali Khodadadi
Journal:  Iran J Basic Med Sci       Date:  2015-01       Impact factor: 2.699

8.  Behavioral and neurophysiological effects of transdermal rotigotine in atypical parkinsonism.

Authors:  Davide Vito Moretti; Giuliano Binetti; Orazio Zanetti; Giovanni Battista Frisoni
Journal:  Front Neurol       Date:  2014-06-05       Impact factor: 4.003

Review 9.  Psychosis in parkinsonism: an unorthodox approach.

Authors:  Marco Onofrj; Danilo Carrozzino; Aurelio D'Amico; Roberta Di Giacomo; Stefano Delli Pizzi; Astrid Thomas; Valeria Onofrj; John-Paul Taylor; Laura Bonanni
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-16       Impact factor: 2.570

10.  Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy.

Authors:  Davide Vito Moretti; Giuliano Binetti; Orazio Zanetti; Giovanni Battista Frisoni
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-05       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.